Skip to content

What is BioDesign?

BioDesign is an expert-guided, collaborative linker development process for bioconjugate therapeutic development.

Selecting and optimizing the right linker for your bioconjugate drug candidate is easy in theory but hard to do alone. BioDesign from Vector Laboratories helps deliver your therapeutic’s potential by harnessing proprietary architectures, incorporating chemical biology expertise, and leveraging more than 20 years of linker experience.

scientist vlabs
Icon 44 Landing
Potency

Leverage your linker design to modify the drug-to-antibody (DAR) ratio so that you can modulate potency and hit your target therapeutic index.

Icon 22 Landing
Stability

A linker needs to provide stability in blood plasma to protect from premature drug release and metabolic liabilities, yet remain labile at the target.

Icon 33 Landing
Hydrophilicity

Linkers can modulate ADC hydrophilicity, improving solubility, minimizing aggregation, and reducing unwanted clearance.

Icon 11 Landing
Homogeneity

Ideal ADC linkers minimize heterogeneity, given that ADCs with mixed structure populations can include fractions with undesirable pharmacological properties and pose analytical challenges.

You’ve never seen ADC’s so happy!

Shielded linkers can make all the difference to the success of your Antibody Drug Conjugates. See how in this delightful animation.

Learn more about these joyful ADCs and the science behind them:

Resources

Advantages of dPEG®
in ADC Linker Design

The curse of low solubility,
high aggregation and low stability

Webinar thumbnail bd

Webinar On Demand

Mitigating ADC Toxicities With Linker-Payload Design

Vebinar thumbnail bd

Webinar On Demand

Influencing Antibody Drug Conjugates through linker design

large thumbnail bd

Explore the BioDesign Core Platform

Learn about the PEG based platform used in our bioconjugate linkers

The Science Behind BioDesign

The BioDesign process combines the long-established dependability of Vector Laboratories in enabling the research objectives of life science customers with new proprietary capabilities and technologies. From understanding your bioconjugates’ unique challenges, to collaborating on linker selection strategy, to manufacturing pure materials at-scale, the BioDesign process provides you with expert-guided linker support.

Explore the possibilitiess

Explore the possibilities

Selecting a linker architecture requires understanding how the relationship between a linker’s structure, drug payload, and drug-to-antibody ratio (DAR) alters efficacy, stability, hydrophilicity, physicochemical properties, and off-target toxicity. BioDesign works through these complexities to build multiple linker options and find the ideal linker that works best.

  • Linear & Branched
    Linear is ideal for loading a single drug onto a single site. Branched includes additional drugs per linker.
  • SideWinder™
    Carries a single payload and orthogonal PEG strand for shielding or modifying biochemical properties.
  • BodyArmor™
    Similar to SideWinder but includes additional attachment points for increased payload with a single conjugation site.
  • Scaffold
    Linkers that mix and match the architectures discussed above.

Design your ADCs with the right partner, right process

BioDesign your ADC candidates and benefit from chemical synthesis mastery, bioconjugation expertise, and 20+ years of linker know-how.

  • Customization
    Develop a linker tailored for your unique ADC.
  • Flexibility
    Off-the-shelf and custom options.
  • Scalability
    Manufacture high-purity linkers to your scale.
  • Domestic supply
    U.S.-based manufacturing and customer service for easy communication and site audits.
Design your ADCs with the right partner right process
Analytical test CoA VL

Design dPEG® linkers with purity and at scale

Producing and purifying monodisperse PEG linkers requires critical synthetic and polymer chemistry expertise and infrastructure. The proprietary dPEG® scaffold and its patented synthetic manufacturing processes enable Vector Laboratories to synthesize monodisperse linkers with longer lengths (>12 EO), orthogonal branching, greater functional group customization, and superior purity.

  • Precise linkers
    Refined linker synthesis and purification methods produce monodisperse linkers, minimizing oligomeric impurities that can create undesired bioconjugate mixtures.
  • Manufacturing
    Proprietary manufacturing processes synthesize linkers with longer lengths and orthogonal branching that contribute to the development of future ADCs.
  • Purity
    Detailed in-house orthogonal assessments minimize impurities without sacrificing drug homogeneity and give a more in-depth picture of impurities to ensure you are getting what you need.
  • Scalability
    Produce high-purity linkers at scale for your project—from discovery to early clinical trials.

Let’s discuss your goals and find the right solution

Stay in the loop. Join Our Online Community.

The latest news, tips, and product releases delivered conveniently to your inbox.

We're Social Scientists! Let's connect.